Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04VQH
|
||||
| Former ID |
DIB005010
|
||||
| Drug Name |
XEN-D0501
|
||||
| Synonyms |
XEN-D501; Ion channel modulator 1 (overactive bladder), Xention; TRPV1 antagonist (overactive bladder), Xention;VR1 antagonist (overactive bladder), Xention; Vanilloid receptor-1 antagonist (overactive bladder), Xention; Ion channel modulator (overactive bladder), Xention/Scion/Bristol-Myers Squibb
|
||||
| Indication | Overactive bladder disorder [ICD9: 188, 596.51; ICD10:C67, N32.81] | Phase 2 | [1] | ||
| Company |
Bristol-Myers Squibb Co
|
||||
| Target and Pathway | |||||
| Target(s) | Vanilloid receptor 1 | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | ||||
| Trk receptor signaling mediated by PI3K and PLC-gamma | |||||
| Reactome | TRP channels | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02233699) A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough. U.S. National Institutes of Health. | ||||
| REF 2 | An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921-31. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.